Privia Health Group, Inc. (NASDAQ:PRVA) Shares Purchased by Algert Global LLC

Algert Global LLC raised its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 639.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 108,048 shares of the company's stock after acquiring an additional 93,429 shares during the quarter. Algert Global LLC owned approximately 0.09% of Privia Health Group worth $2,112,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of Privia Health Group by 1.3% in the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company's stock valued at $5,615,000 after purchasing an additional 3,658 shares during the period. Nordea Investment Management AB increased its stake in Privia Health Group by 33.1% in the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock valued at $6,953,000 after purchasing an additional 86,910 shares during the period. Franklin Resources Inc. increased its stake in Privia Health Group by 2.2% in the third quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock valued at $23,092,000 after purchasing an additional 28,480 shares during the period. Barclays PLC increased its stake in Privia Health Group by 240.3% in the third quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after purchasing an additional 158,188 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Privia Health Group by 8.4% in the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock valued at $3,430,000 after purchasing an additional 14,641 shares during the period. 94.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on PRVA shares. Barclays increased their price objective on Privia Health Group from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 10th. Robert W. Baird increased their price objective on Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 15th. JMP Securities reaffirmed a "market outperform" rating and set a $29.00 price objective on shares of Privia Health Group in a research report on Monday, April 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. Finally, Canaccord Genuity Group increased their price objective on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Privia Health Group currently has an average rating of "Buy" and a consensus price target of $27.38.

Insider Buying and Selling

In related news, CEO Parth Mehrotra sold 15,100 shares of Privia Health Group stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $352,283.00. Following the completion of the transaction, the chief executive officer now directly owns 454,281 shares of the company's stock, valued at approximately $10,598,375.73. The trade was a 3.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO David Mountcastle sold 5,630 shares of Privia Health Group stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total value of $125,999.40. Following the transaction, the chief financial officer now directly owns 179,676 shares of the company's stock, valued at approximately $4,021,148.88. This represents a 3.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,484 shares of company stock valued at $799,163. 10.70% of the stock is owned by insiders.

Privia Health Group Trading Up 0.2%

Shares of PRVA traded up $0.04 during mid-day trading on Monday, hitting $25.06. The company's stock had a trading volume of 948,250 shares, compared to its average volume of 767,076. The firm has a 50-day simple moving average of $23.38 and a 200 day simple moving average of $22.34. The firm has a market capitalization of $3.04 billion, a P/E ratio of 250.63, a P/E/G ratio of 3.47 and a beta of 0.87. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $26.09.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.